AuthorInformation providedat end of text. theannalscom BACKGROUND: Despite the well-known beneficial effectsof statins, many patients do not adhere to chronic medication regimens. OBJECTIVE: To implement and assess the effectiveness of a community pharmacy-based pharmaceutical care program developed to improve patients' adherence to statin therapy.
D espite the well-known beneficial effects of statins , adherence to statin treatment is poor in daily medical practice. One-year persistence with statins has been estimated to be about 60% in patients with previous cardiovascular events'"; in primary prevention, discontinuation rates are likely to beeven higher. 3 ,4 Poor adherence is a major barrier to successful treatment. Therefore, potential benefits of statins as established in randomized controlled trials may not be accomplished in clinical practice. Both the World Health Organization and the European Council have advocated for a multidisciplinary approach in addressing nonadherence. In this approach, 'the community pharmacist has an important . role to play in ensuring that drug therapy is appropriate and the patient has an optimal chance of success with therapy.v' Community-based pharmacists are the most easily accessible health-care providers, have extensive knowledge about drug therapy and disease management, and can provide information and education to the patient and monitor adherence.
Several randomized controlled trials have been conducted in which pharma- SRBM Eussenet al. ceutical interventions to enhance medication adherence have been implemented.l'" Evaluated interventions range from giving patients more information and education on the goals and benefitsof drug therapy to the simplification of the drug regimen and intensification of patient care by telephone reminders, home visits, and follow-up interviews. Most randomized controlled trials showed beneficial effectson adherence,IO,15,17 lipid levels, ',8,13,14,16 or both," Moreover, overallhealth-care expenditures in the intervention and control groups seem to be similar, despite increasedvisitsto the pharmacist and laboratory costs,"
It has been shown that the most critical need for adherence interventions is during the first few months of therapy, as adherence levelsdrop shortly afterinitiation of statin treatment." Hence,persons who have been newly prescribedmedications comprise an interesting subgroup when pharmaceutical care programs are implemented. Most studies aimed at improving adherence among users of statins werehospital pharmacy-based,7.I0,14,16 sometimes withcomplex interventions'v'v" and mostly not focusing solely on patientsinitiating statintreatment. 7,8,IO. 14, 16 We thereforedeveloped a large multicenter community pharmacy-based pharmaceutical care programfor new statin users. This program was aimed at improving adherence to statin therapy by givingpatients education and feedback on achieved lipid levels. These interventions are easy to implement in community pharmacies, are relatively inexpensive, and have been shownto be effective in clinical trialswith various patient populations.i-" The purpose of our study was to examine the feasibility and effectiveness of this program.
Methods

STUDY POPULATION
Our study,the STIPf (STatin Intervention researchPro-jecT), was a community pharmacy-based, multicenter, open-label, randomized controlled trial to improve medication adherence in new users of statins, Patients were recruitedfrom 26 communitypharmacies (both independent and chain stores) in the Netherlands and were eligible for inclusion if they were new users of statins, were aged 18 years or older, and were capable of visiting the pharmacy. New users were defined as those who had not filled a prescriptionfor statins in the preceding6 months, verified by the pharmacistthrougha patientrecord check. VIrtually all Dutch inhabitants are registered'with a single community pharmacy,independentof prescriber; consequently, pharmacy records are nearly complete with regard to prescription drugs," The studywas approved by the MedicalCommittee of Ethics of the UniversityMedical Centre Utrecht and all patientssigned informedconsentforms prior to the study. Study enrollment started in September 2004 and was completedin March 2006.
STUDY DESIGN
Once the informed consent form was received, each participant was randomly assigned to eitherthe intervention or control groupby a procedure that was built intothe computersystem anduseda setof random numbers in a 1:1 ratio. Patients in the intervention (pharmaceutical care) groupwere invited to visitthe pharmacy for 5 individual counseling visits,eachlasting 10-15 minutes. Counseling visits werescheduled at first prescription, at second prescription (after 15 days), andat subsequent refill datesat 3, 6, and 12 months after the startof statin therapy. In the Netherlands, the first prescriptionfor statins is limited to 15 days20 and subsequent prescriptions are generallydispensedin 3-month supplies. Because it hasbeenshown thatpatients aremostlikely to discontinuestatinsin the first monthsafter therapyinitiaticn.P counseling sessions were scheduled more frequently during the firstmonths of treatment. Counseling at timeof firstprescriptioncomprisedstructurededucationon indication, effects, and adverseeffectsof statin therapy;dosage; importance of medication adherence; and intended duration of treatment. Additionally, a drug information letter that summarized the verbal information wasgivento each patient. At thetimeof the second prescription, patients wereaskedabout their experience with statin therapy,potentialdrug-related problems, and difficulties in adhering to the dosingregimen. At 3, 6, and 12 months, total cholesterol, high-density lipoprotein cholesterol, and triglyceride levels weremeasured from fasting fingerstick whole· blood samples using CholestechLDX Analyzers (CholestechCorp., Hayward, '"CA) and low-densitylipoprotein cholesterol (LDL-C) was estimated by the Friedewald formula," Measured lipidlevels and treatment goals wererecorded on a walletcard that was keptby allpatients to monitor theirprogress in lowering lipid levels.In addition, medication adherencewas assessedvia unused pill counts, and the association between adherence andlipidlevels wasdiscussed to encourage patients to adhere to theprescribed dosing regimen.
Patients in the control group were provided usual care, consisting of verbal and written drug informationaccording to the standard protocol in the pharmacies. Patients in the usual care group did not receivelipid measurements or counseling sessions.
In both the pharmaceuticalcare and usual care groups, patients were asked to fill outa questionnaire at baseline and after 6 and 12 months. The baseline questionnaireincluded items on sociodemographics, family history of cardiovasculardisease (CVD), comorbidities,self-perceived health, lifestyle factors (smoking habits,alcohol consumption, dietary habits),and the application of other lipid-lowering strategies (eg, eating healthier or becoming more physically active). Questionnaires at 6 and 12 monthscontainedquestions aboutchangesin self-perceived healthand lifestyle modifications to lower lipid levels.
All questionsabout the study or treatmentfrom patients in both treatment arms were answered as forthrightly as possible. Participants and thoseadministering the interventions were not blinded to the treatment assignment. Conversely,those assessing differences in outcomes between the pharmaceutical care and usual care groups remained blindedthroughout the study.
OUTCOME DEFINmON
Electronic pharmacy dispensing records of all patients were collected at the end of follow-up. Adherence to statins was evaluated in terms of discontinuation of treatment and the medication possession ratio (MPR). 22 The primary endpoint of this studywas discontinuation of treatment assessed I year after the start of statin therapy. Secondaryendpoints were discontinuation rates 6 months after statin initiation, theMPR,and therelation between MPR and totalcholesterol andLDL-Clevels. Patients wereconsidered to havediscontinued therapy if theyfailed to refill theirstatin agents within 90 daysor I timethe theoretical duration of the prescription, whichever was the lowest number of days.23 Time to discontinuation was definedas the number of days between the start of statin therapy and the discontinuation day.When a patientrefilled a prescription for the same type of statinbeforethe theoretical end date of the previousprescription, we assumedthat the new prescription began after the end date of the previous one," Patients who switched fromone typeof statio to another wereconsidered to be continuous users. Patients werecensored at the end of the study period or whentheychanged to a pharmacy not participating in the study or diedbefore theendof follow-up. The patient's MPR was assessed from the pharmacy dispensing records at the end of the studyor,for patients who stopped statin therapy earlier, at the time of discontinuation. The MPR was calculated as theratioof the sum of the days' supply of all statio medication dispensed divided by the length of therapy. A patient with an MPR of 0.9 or more was defined as being adherent to the prescribed dosingregimen.Medication adherence assessedby pill counts duringthe counseling sessions was not regardedas an outcomeof this study but was used solely to instantlyaddress an individual'sadherenceat the counseling session.
STATISTICAL ANALYSIS
A Pharmaceutical Care Program to Improve Adherence to StalinTherapy groups and an expected loss to follow-up of 20%, a sample sizeof 493 patients in eachgroup (986total) wasrequired.
Patientcharacteristics were compared between the pharmaceutical care and usual care groups using an independent sample Student's r-testor X 2 test as appropriate. Discontinuation was estimatedby using Kaplan-Meier analysis and was compared between the groups with a log-rank test. Univariate Cox proportional hazardmodels were used to compare further the probability of discontinuation between the groups. In addition, Cox proportional hazard modelswere used to estimatethe probability of discontinuation at 12 months in various exploratory subgroups that were definedby factors potentially associated with discontinuation.Those factors were age, sex, level of education, comorbidities (hypertension, diabetes, history of CVD), familial hypercholesterolemia, the application of other lipidlowering strategies, and the number of medications used (at Anatomical Therapeutic Chemical [ATe] classification level 3).26 A treatment-by-subgroup interaction term was added to the model to test whetherdifferent subgroups had different risks. The MPR between the 2 study groups was analyzed using the nonparametric Mann-Whitney U test and the percentage of subjects having a high (<:=90%) or low «90%) MPR was compared using the X 2 test. The number of subjects switching to a statinwith a different equipotency score (measure for the potency of a statin to lower total cholesterol according to type and dose)" was computed and comparedbetween the pharmaceutical care and usualcare groupswith the Mann-Whitney U test.
Lipid levels were measured only in the intervention group as part of the pharmaceutical care program; therefore, the effectof differences in MPR on lipid levels could be estimated only in these subjects. Patients were considered to have met lipidtreatment goals if they achievedfasting totalcholesterol levelsof <190 mg/dL and LDL-C levels of <115 mgldL. 28 ,29 The percentage of subjects reaching lipid goals among patients with a high (<:=90%) or low «90%) MPR was compared using the X 2 test. Spearman correlation was used to determine the relationship between the MPR and lipidlevels.
The results wereconsidered statistically significant at a 2sided probabilitylevel ofp < 0.05. All statisticalanalyses wereperformed according to the intention-to-treat principle using SAS version 9.13 (SAS Institute, Cary,NC).
Results
PATIENT ENROLLMENT ANDBASEUNE CHARACTERISTICS
A total of 1016 subjects were enrolled in the trial, 513 (50%) of whom were randomized to the pharmaceutical care group and 503 (50%) to the usual care group ( Figure  1) . A total of 117patients were excluded because no pharmacy dispensing data were available for these subjects, Necessary sample sizewas estimated with the assumption of a l-yeardiscontinuation rateof 33% in the control group, as suggested by a previous study in a comparable patient population," and of 24% in the pharmaceutical care group. The pharmaceuticalcare discontinuation rate was chosen conservatively basedon previous effects of community pharmacy-based programs.IS,!7 Withan 80%powerof detecting a significant difference (p =0.05, 2- Table 1 . Meanage of all participants was 60.1 ± 11.1 years and 49% weremale. Mostpatient characteristics were similar betweenthe groups. However, significantly more patients in the usual care group had a history of CVD, and those in the usual care group classifiedtheir health status more often as moderate/poor. Significantly more patients in the pharmaceutical care group were prescribedatorvastatin, whereas fewer pharmaceutical care patients were prescribedrosuvastatin. A substantialnumber of patients (52%) started statin therapy at a medium equipotency score,equivalent to a simvastatin dose of 20 mg/dayor an atorvastatin doseof 10mg/day. Figure 2 presents the Kaplan-Meiercurve, comparing discontinuation of statin therapy overtimebetween patients in the pharmaceutical careandusual caregroups. Of the 899 patients,58 were censored (20 in the pharmaceutical care group and 38 in the usualcare group)because theydied or left thestudypharmacy before the end of follow-up. A total of 47 (11%)patients in thepharmaceutical caregroup and72 (16%)patients in the usual care groupdiscontinued statins within 6 months afterthe initiation of treatment (p valuefor log-ranktest = 0.026).The corresponding percentages at 1 yearafterthestartof therapy were23%and26%,respectively,in the pharmaceutical careandusual caregroups (p value for log-rank test= 0.21). The hazard rateratioof discontinuing statin therapy, as determined by the Cox proportional hazardanalysis, showedthat patients in the pharmaceutical caregrouphad a statistically significantly lowerrateof discontinuation within 6 months afterinitiating therapy thandid patients in the usual care group (HR 0.66, 95% CI 0.46 to 0.96).Thus,patients in the pharmaceutical caregroupwere 34% less likely to discontinue treatment, or 152 (95% CI 1.04 to 2.17) times more likely to persist with treatment compared to patients in theusual caregroup. Twelve months after therapy was initiated, this difference in discontinuation rate was not statistically significant(HR 0.84, 95% CI 0.65 to 1.10).
DISCONTINUAnON OFSTAnN TREATMENT
Analyses of discontinuation rates by subgroups areshown in Figure 3 . Wenoted a significant treatment-by-subgroup interaction between patients using s5 or >5 medications at the ATC3-level (treatment-by-subgroup interaction, p =0.028), whichindicated that patients using more medications were lesslikely to benefit fromthe pharmaceutical care program. Although patients aged 50 years or younger, females, the highereducated, and patients who did not implement other lipid-lowering strategies seemedto gain more benefit from receiving pharmaceutical care,thedifferences in effect of the pharmaceutical care program between the subgroups were notstatistically significant.
MEDICAnON POSSESSION RAno AND STAnN ADJUSTMENTS
The median MPR (25th-75th percentile) was 99.5% (96.9-100%) in the pharmaceutical care group and 99.2% duringthe study. The averagereduction in total cholesterol and LDL-C was 17.2 mg/dL (95% CI 12.3 to 22.0) and 9.47 mg/dL (95% CI 5.02 to 13.9), respectively. Three monthsafterinitiating statintherapy, 65% of thesesubjects reachedthe targetLDL-C level of below 115 mg/dL.At 6 and 12 months after treatment, these percentages were 72% and 77%, respectively. A higherpercentage of adher-A Pharmaceutical Care Program to Improve Adherence to Stiltin Therapy ent patients (MPR 2:90%) than nonadherent patients reached targetLDL-Clevelsafter 3 months(67% vs 45%, respectively; p = 0.01) and 6 months (74% vs 50%. respectively; p = 0.01). Spearman'scorrelation showeda significant negative association between the MPR and total cholesterol (r = -0.16; P = 0.002) and a trend toward a negative association between the MPR and LDL-C level(r =-0.10; P =0.08). 
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Discussion
Patients who understand the benefits of treatment and are satisfied with health-care providercommunication, and those with frequent follow-up lipid tests, have been shown to be moreadherent to statintherapy."In our study,a community pharmacy-based pharmaceutical care program composedof patientcounseling and feedback on achieved lipid levels was associated with modestly lower discontinuation rates of statin therapy. Compared to patients in the usual care group, those in the pharmaceutical care group were 34% less likely to discontinue treatment within 6 months(p =0.03) and 16% less likelyto discontinue treatment within 1 year after initiating statin therapy (p =NS).
This difference in effecton discontinuation ratesbetween6 and 12 months might imply thatfrequent counseling sessions (every3 months) are necessary to maintain the positiveeffects. However, thefactthatthedifference between groups in discontinuation rates at 12 monthsdid not reach statistical significance couldalso be explained by otherfactors. Most importantly, discontinuation rates in the usual care group were lower than anticipated. The marginfor improvement was therefore lessthanthathypothesized in thepowercalculation. Thismight be duetothefactthatadherent patients and pharmaciesthat had already beeninvolved in advanced provision of pharmaceutical care were more willingto participate in the program. Moreover, adherence to therapyin the usual caregroup might havebeenenhanced because thesubjects were aware that their behaviorwas being monitored. Severalstudiesaimed at improving adherence have shown unexpected highadherence in usualcaregroUpS. 31,u The fact that patients included in the studyreported a relatively high proportion of health-promoting behavior modifications suggests thatstudy patients weremoreaware of their lipidlevels andcardiovascular risk.Therefore, theeffect of thispharmaceutical care program on adherence mightbe higherin routinemedical practice.
Anotherreasonfor the lack of effectof the phannaceutical care program on l-year discontinuation rates is that 19% and 31% of the patients randomized to the pharmaceutical care group did not attendthe follow-up counseling session at 6 and 12 months, respectively. Patients not adheringto the study protocol cannotbenefit optimally from the program, leading to a diluted treatment effect. When this programis being implemented indailymedical practice, an effort should be made(eg,by sending reminders and contacting patients who did not show up for their scheduled counseling session) to ensure thatpatients adhere to thecounseling sessions. In our study, we present onlyresults obtairied froman intention-to-treat analysis. Analyzing results according to the per protocolprincipleof includingonly patients whohadat least1 follow-up counseling visit couldintroduce selection bias" due to associations between discontinuation of statin therapy and study dropout.
Finally, significantly more patients in the usual care groupreported a history of CVD. This mighthave affected our results, as it is knownthat persistence with statintherapy is betteramong patients with preexisting CVD.34 However,including CVD statusas a confounder in Cox proportional hazardanalysis did not changeour results.
Although not statistically significant, the pharmaceutical care program seemed to be more effectivein younger patients, females, the highereducated, and patients not taking many other medications (ie, patients generally classified as havinga lower cardiovascular risk profile).Severalobservational studies have shownlowerstatin adherence among these patients. 35 • 38 Therefore, the margin of improvement mightbe greaterin thesesubgroups.
Despite the highMPR,we found significant associations betweendifferences in the MPR and totalcholesterol-and LDL-C-lowering effects. Because lipid levels were measured only in the pharmaceutical care group, we were not ableto study the effects of the pharmaceutical care intervention on lipidlevels; Measuring lipidvalues in~e usualcare group probably would haveinfluenced patients' behavior and thereby would have increasedadherencein the usual care group. As a result,the effectof the intervention wouldhave beendiluted. However, as discussed earlier, it is still conceivable that adherence to therapy is higher in the usual care group compared to daily medical practice.
We did not observe more patients switchingto another type or doseof statinin the pharmaceutical care group.Apparently, measuring lipid levels can be seen primarilyas a method to give feedback to patients on the effect of statin treatment and does notresult in adjustments of drug therapy. However, a lack of feedback from the pharmacist to the physician might alsobe a reason for theabsence of dosage or drugadjustments.
In our study we used pharmacy dispensing data to calculate patient adherence to statin medication.These data presentmany advantages over self-reported adherence and medical records. Dispensing data are not suspectto patientrelated recallbias and reduce nonresponse bias. However, uncertainty still exists as to whether dispensed drugs are actuallybeing taken according to the prescribedregimen. In a study monitoring patient adherenceto lipid-lowering therapy in clinical practice-it was found that, during the monitoring period of 6 months,approximately 60% of patients erroneously took multipledoses of statins per day,"
In addition, we did not have information for many patients about the reason for discontinuation, and therefore we wereunable to assess whether statintherapy wasdiscontinued for clinical reasons. However, this wouldseem uncommon, as statin therapy is mostly indicatedover a patient's lifetime and statins have a relatively mild adverse event profile." Another limitation of our study is that we could not perform a double-blind study becauseof the nature of the intervention studied in this trial.
We recognize that randomization at the patient level, rather than at the pharmacylevel,may havecontaminated the care receivedby the patientsin the usualcare groupby pharmacists' knowledge of the pharmaceutical careprogram. This wouldhave increased the risk of a type II error (ie, incorrectly accepting the null hypothesis) and therefore could havediluted theeffect size. In ourstudy, however, extratime was scheduled for patients in the pharmaceutical care group for measuring the lipid levels and for counseling. Patients randomized to the usual care group visited the pharmacy only to refill their statin prescription. The alternative of a cluster-randomized trial would havegivenriseto otherproblems,suchas recruitment bias,since participants arerecruited aftertheclusters havebeenrandomized. 41 • 43 In conclusion, we demonstrated the feasibility and effectiveness of a community pharmacy-basedpharmaceutical careprogram to improve medication adherence in new users of statins. Although improvements in adherence were modest,the program is convenient forthe patients because counseling sessions are linked to the prescription refill dates. Moreover, the interventions are relatively inexpensive and easy to implement; the lipidtestscost about$80 per patient and counseling sessions take an additional hourper patient. Therefore, theprogram canbe applied easily to a larger population and have a large impact on populationlevel. Health economic studies should be performed to fully assess the cost-effectiveness of thispharmaceutical careprogram.
METODOLOGfA: Estudioabierto,prospective, aleatorizado, y controlado se realiz6en 26 farmacias de comunidaden los parsesBajos.Los nuevos pacientes de las estatinas con 18afios 0 mas fueron asignados aleatoriamente para recibirla atenci6nhabitual0 una intervenci6n farmaceutica, La intervenci6n consisti6en 5 sesiones de consejeria A Pharmaceutical CareProgram to Improve Adherenceto Statin Therapy individual por un farmaceutico duranteun perfodo de 1 ano. Durante estassesiones.Ios pacientes recibieron educaci6n estructurada sobrela importancia de la adherencia a los medicamentos. Los niveles de Ifpidos fueron medidos y la asociaci6n entre los niveles de adherencia y los niveles de Ifpidos fueron discutido. Laadherencia a la terapia conestatinas se evalu6con las tasasde descontinuaci6n en 6 y 12mesesdespues del iniciode las estatinas y la relaci6n de posesi6n de medicamentos (MPR).
RFSULTADOS: Un totalde 899 sujetos(439en el grupode cuidadofarmaceutico y 460 en el grupode cuidadohabitual) fueronevaluados parael analisis de la eficacia.El programa de cuidadofarrnaceutico result6en una una tasa significativamente Menor en la descontinuaci6n dentrode los 6 mesesdespues de iniciarel tratarniento (HR 0.66,CI 95% 0.46-0.96).No hubodiferencia significativa entre los gruposen la descon-tinuaci6n en los 12meses(HRO.84,CI 95%0.65-1.10).MPR fue muy alto(>99%)en ambosgruposy no hubodiferencia entre los grupos, CONCLUSIONES: Se demostr6 la viabilidad y eficaciade un prograrna de cuidadofarmaceutico en la farmacia de comunidad paramejorarla adherencia a los medicamentos en los nuevos usuarios de estatinas. Sesiones de consejerfa frecuentes (cada3 meses)son necesarios para mantener los efectos positivos de la descontinuaci6n. Aunque las rnejorfas son modesta,el programa puedeser facilrnente aplicado a una poblaci6n masgrande y tenerun granimpacto; y lasintervenciones sonrelativarnente pocoscostosas y faciles de implementar en la practicaclfnica. MtrHODES: Uneetudeouverte,prospective, randomisee a ete effectuee dans 26 officines aux Pays-Bas. Les nouveaux utilisateurs de statines ligees de plusde 18ans ont ete repartis au hasardpourrecevoirdes soins usuelsou l'intervention d'un pharmacien. Les interventions consistaient en 5 sessions individuelles de conseilsaux patients effectuees parIe pharmacien durantune perioded'une annee,Au coursde ces sessions, les patientsont recu de I'information structuree concernant I'importance de prendreses medicaments.les ciblesviseesde cholesterol et l'association entre l'adhesionet les niveaux de cholesterol. L'adhesion a la prisedes statines a ete mesuree selonIe tauxd'arret II 6 et 12 mois suiteII la phased'initiationde la statineet Ie ratiode possession de medicaments.
RFsuLTATS: Un nombre de 899patients (439dans Iegroupesoinspharmaceutiques et 460dansIegroupe soinsusuels) a ete evalue. Le programme de soinspharmaceutiques a eu un tauxd'arret signiticativement plus bas en dedansde 6 moisdu debutdu traitement (HR 0.66;95%CI 0.46-0.96).Aucunedifference significative entre les 2 groupesn'a ete observeedans l'arret du traitement II 12 mois(HR 0.84;95% CIO.65-1.10).Le ratiode possession de medicament etait Ireseleve(>99%)dans les 2 groupessoit pour Ie groupede soinspharmaceutiques et pour Ie groupede soins,usuels et il n'y avaitpas de difference entreles 2 groupes. CONCLUSIONS: Les auteursont demontre la faisabilite et l'efficacited'un programme de soinspharmaceutiques pour ameliorerl'adhesionchez des nouveaux utilisateurs de statines. Des sessions d'information regulieres (aux 3 mois)sont neeessaires pour maintenir les effetspositifs. Meme si les ameliorations sontmodestes,le programme pent etre facilement mis en placeet avoirdes impactsirnportants puisqueles interventions ne sontpas dispendieuses et faciJement misesen place.
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